2010
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†
Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK, Group F. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†. Neuro-Oncology 2010, 12: 871-881. PMID: 20511192, PMCID: PMC2940677, DOI: 10.1093/neuonc/nop054.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsBrain NeoplasmsCarmustineCatheters, IndwellingConvectionDecanoic AcidsDrug Administration RoutesExotoxinsFemaleGlioblastomaHumansInterleukin-13Kaplan-Meier EstimateMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalPolyestersRecombinant Fusion ProteinsYoung AdultConceptsConvection-enhanced deliveryCintredekin besudotoxGliadel wafersMedian survivalTumor resectionGlioblastoma multiformeEfficacy-evaluable populationAdverse event profileHealth-related qualityPhase III evaluationTime of randomizationEvaluable populationTertiary endpointsPrimary endpointAdult patientsBaseline characteristicsFirst recurrenceOverall survivalPulmonary embolismActive comparatorTreatment armsIL13-PE38QQRIntraparenchymal catheterSurvival differencesGBM patients
2006
Chondrosarcoma of the Skull Base
Baehring JM, Piepmeier J, Duncan C, Liebsch N, Ogle E, Kim J. Chondrosarcoma of the Skull Base. Journal Of Neuro-Oncology 2006, 76: 49-49. PMID: 16402277, DOI: 10.1007/s11060-005-5981-3.Peer-Reviewed Original Research
2005
Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas
Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT. Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas. Cancer Research 2005, 65: 6726-6733. PMID: 16061654, DOI: 10.1158/0008-5472.can-05-0585.Peer-Reviewed Original ResearchConceptsBEHAB/brevicanHigh-grade gliomasMalignant gliomasBrain tumorsNew potential therapeutic targetsPrimary brain tumorsNormal adult brainDeadly brain tumorCentral nervous systemPotential therapeutic targetLow-grade gliomasHuman malignant gliomasNew therapeutic strategiesPathologic courseSimilar histologyBenign gliomasAdult brainTherapeutic strategiesDiffuse invasionTherapeutic targetGlioma progressionNervous systemInvasive abilityBrain tissueGliomas
2004
Tumors of the posterior third ventricle and pineal region: ependymoma and germinoma
Baehring J, Vives K, Duncan C, Piepmeier J, Bannykyh S. Tumors of the posterior third ventricle and pineal region: ependymoma and germinoma. Journal Of Neuro-Oncology 2004, 70: 273-274. PMID: 15674486, DOI: 10.1007/s11060-004-5395-7.Peer-Reviewed Original Research
2001
Patterns of functional magnetic resonance imaging activation in association with structural lesions in the rolandic region: a classification system.
Carpentier A, Constable R, Schlosser M, de Lotbinière A, Piepmeier J, Spencer D, Awad I. Patterns of functional magnetic resonance imaging activation in association with structural lesions in the rolandic region: a classification system. Journal Of Neurosurgery 2001, 94: 946-54. PMID: 11409524, DOI: 10.3171/jns.2001.94.6.0946.Peer-Reviewed Original ResearchConceptsFMR imaging activationSurgical interventionRolandic regionMotor cortex plasticityMotor task paradigmFunctional magnetic resonance imagingMotor skillsMagnetic resonance imagingSevere motor impairmentFunctional magnetic resonanceFunctional recoveryLesion sideCortical abnormalitiesMotor cortexControl volunteersCortical malformationsStructural lesionsContralateral hemisphereArteriovenous malformationsBrain lesionsSurgical proceduresMotor impairmentPathological lesionsFunctional reorganizationAuthors' institution
1997
Low-grade gliomas of chronic epilepsy: A distinct clinical and pathological entity
Bartolomei J, Christopher S, Vives K, Spencer D, Piepmeier J. Low-grade gliomas of chronic epilepsy: A distinct clinical and pathological entity. Journal Of Neuro-Oncology 1997, 34: 79-84. PMID: 9210054, DOI: 10.1023/a:1005711321343.Peer-Reviewed Original ResearchConceptsLow-grade gliomasChronic epilepsyDysembryoplastic neuroepithelial tumorPathological entityLong-term patient outcomesSpecific pathological entityManagement of patientsResults of patientsDistinct pathological entityLack of mortalityPreoperative seizuresNeuroepithelial tumorsTumor recurrencePatient outcomesAnaplastic transformationEpilepsySame tumorGliomasCortical locationTumorsPatientsRecurrenceSeizuresPopulationMortalityAdministration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277: 1597-604. PMID: 9168289, DOI: 10.1001/jama.277.20.1597.Peer-Reviewed Original ResearchConceptsAcute spinal cord injurySpinal cord injuryNational Acute Spinal Cord Injury StudyFunctional Independence MeasureHours of injuryCord injuryTirilazad groupRegimen groupMethylprednisolone infusionAcute Spinal Cord Injury StudySpinal Cord Injury StudySpinal cord injury centerEfficacy of methylprednisoloneImproved motor recoveryMotor recovery rateAdministration of methylprednisoloneMotor function changesSteroid therapyMethylprednisolone groupSevere sepsisTirilazad mesylateMotor recoveryControlled TrialsInitial presentationIntravenous bolus
1996
BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines.
Jaworski D, Kelly G, Piepmeier J, Hockfield S. BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Research 1996, 56: 2293-8. PMID: 8625302.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnimalsBiomarkers, TumorBrain NeoplasmsBrevicanCarrier ProteinsChild, PreschoolChondroitin Sulfate ProteoglycansFemaleGliomaHumansHyaluronic AcidIn Situ HybridizationLectins, C-TypeMaleMiddle AgedNeoplasm InvasivenessNeoplasm ProteinsNeoplasm TransplantationNerve Tissue ProteinsRatsRats, Inbred LewRats, Sprague-DawleyTumor Cells, CulturedConceptsGlioma cell linesSurgical samplesIntracranial graftsCell linesAdult human cortexInvasive glioma cell linesBrain metastasesNonglial tumorsNoninvasive cell linesMalignant gliomasExtracellular brainNormal brainTumor invasionHyaluronan-binding proteinHuman cortexGliomasTumorsInvasive behaviorStandard cell culture conditionsGraftBrainBEHABCell culture conditionsSelective markerMetastasis
1993
Low-grade astrocytomas may arise from different astrocyte lineages.
Piepmeier J, Fried I, Makuch R. Low-grade astrocytomas may arise from different astrocyte lineages. Neurosurgery 1993, 33: 627-32. PMID: 8232801, DOI: 10.1227/00006123-199310000-00010.Peer-Reviewed Original ResearchConceptsLow-grade astrocytomasGlial fibrillary acidic protein-positive cellsFibrillary acidic proteinProtein-positive cellsAstrocyte lineagePreoperative symptomsAnti-glial fibrillary acidic proteinAcidic proteinGlial fibrillary acidic proteinLong preoperative historyCommon histological featuresDifferent clinical manifestationsPercentage of cellsPreoperative historyClinical manifestationsHistological featuresImaging featuresRate of proliferationImmunohistochemical analysisAstrocytic phenotypeNeoplastic cellsType 2White matterAstrocytomasTumors
1990
A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury
Bracken M, Shepard M, Collins W, Holford T, Young W, Baskin D, Eisenberg H, Flamm E, Leo-Summers L, Maroon J, Marshall L, Perot P, Piepmeier J, Sonntag V, Wagner F, Wilberger J, Winn H. A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury. New England Journal Of Medicine 1990, 322: 1405-1411. PMID: 2278545, DOI: 10.1056/nejm199005173222001.Peer-Reviewed Original ResearchConceptsAcute spinal cord injurySpinal cord injuryNeurologic recoverySafety of methylprednisoloneSystematic neurological examinationPlacebo-controlled trialHours of injuryMajor morbidityNeurologic outcomeControlled TrialsNeurological examinationIncomplete lesionsMotor functionMethylprednisoloneNaloxonePatientsBody weightSensory functionInjuryPlaceboInfusionBolusEffective remainsTreatmentDose
1988
Late neurological changes following traumatic spinal cord injury.
Piepmeier J, Jenkins N. Late neurological changes following traumatic spinal cord injury. Journal Of Neurosurgery 1988, 69: 399-402. PMID: 3404238, DOI: 10.3171/jns.1988.69.3.0399.Peer-Reviewed Original ResearchConceptsSpinal cord injuryTraumatic spinal cord injuryCord injuryNeurological functionPatient's spinal cord injuryFunctional neurological statusFrankel scaleNeurological statusNeurological examinationSpinal traumaYears postinjuryNeurological changesPatient statusInjuryMajority of improvementsPatientsExaminationSignificant changesStatusYearsPostinjuryHospitalTrauma
1987
Cardiovascular abnormalities accompanying acute spinal cord injury in humans: Incidence, time course and severity
Lehmann K, Lane J, Piepmeier J, Batsford W. Cardiovascular abnormalities accompanying acute spinal cord injury in humans: Incidence, time course and severity. Journal Of The American College Of Cardiology 1987, 10: 46-52. PMID: 3597994, DOI: 10.1016/s0735-1097(87)80158-4.Peer-Reviewed Original ResearchConceptsCord injurySpinal cordCardiovascular abnormalitiesAcute spinal cord injuryAcute severe injuryCervical cord injuryPrimary cardiac arrestCervical spinal cordSpinal cord injuryLife-threatening disturbancesMild cervical injuriesPersistent bradycardiaAutonomic imbalanceCervical cordHemodynamic abnormalitiesInjury groupSympathetic pathwaysConsecutive patientsCord traumaCervical injuryAcute injurySupraventricular arrhythmiasCardiac arrestSevere injuriesDay 4
1985
A phase I trial of naloxone treatment in acute spinal cord injury.
Flamm E, Young W, Collins W, Piepmeier J, Clifton G, Fischer B. A phase I trial of naloxone treatment in acute spinal cord injury. Journal Of Neurosurgery 1985, 63: 390-7. PMID: 3894597, DOI: 10.3171/jns.1985.63.3.0390.Peer-Reviewed Original ResearchConceptsGroup 2 patientsSpinal cord injuryAcute spinal cord injuryPhase I trialTime of admissionLoading doseCord injuryMaintenance doseI trialExperimental spinal cord injuryComplete neurological deficitGroup 1 patientsWeeks of admissionDose-related fashionTreatment of patientsOpiate antagonist naloxoneIncomplete deficitsMaintenance infusionNeurological deficitsNeurological statusNaloxone treatmentNeurological examinationAntagonist naloxoneInitial doseContinuous infusion